Full-Time

Area Vice President Sales

Sales

Posted on 5/9/2026

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

No H1B Sponsorship

Boston, MA, USA + 2 more

More locations: Philadelphia, PA, USA | New York, NY, USA

In Person

Must reside in the Metro NYC, Boston, or Philadelphia markets.

Category
Sales & Account Management (2)
,
Required Skills
Sales
Forecasting
Marketing
Requirements
  • 12+ years of surgical sales experience, preferably in a strategic sales, training, or sales leadership
  • Proven track record of meeting or exceeding sales targets and driving growth in competitive markets
  • Bachelor’s degree in business, marketing, sales, or a related field
  • It is a requirement to live in the Area under which you have responsibility
  • Must be able to travel up to 75% of the time
  • Works in the field with customers, Sales Representatives, a minimum of 60% of the work week
  • Applicants must already have full-time work authorization in the United States, both now and in the future, without requiring sponsorship
Responsibilities
  • Set a vision for area sales force that aligns the field sales organization around the company vision and strategic plans
  • Based on overall business plan and understanding of accounts and territories, develops plans and sets priorities to achieve monthly, quarterly and annual sales and revenue goals
  • Develop and implement comprehensive sales strategies targeting key surgeons, new markets, and growth opportunities
  • Engage Field Selling Organization on Sales Funnel adoption; lead generation, qualifying, presenting, training, closing
  • A strong level of experience with Enabling Technology both clinical and in Capital sales is strongly preferred
  • Assist distributors and representatives with sales calls on all product lines within the business. Focusing on New Product Introductions launches and critical product categories
  • Align with sales leadership and Field Sales Team on strategic and/or critical case coverage needs
  • Work with the Commercial Education team to assist in the training and education of new Sales Representatives. This would also include New Product Introductions launches for the entire Selling Organization
  • Attains quarterly and annual business plan, revenue, and gross profit objectives
  • Manages budget/spend to ensure monthly, quarterly and annual spending is within financial plan
  • Carefully reviews expense reports and provides guidance on appropriate use of Company funds and resources. Ensures regional expense reporting is accomplished in a timely manner
  • Performs sales analysis trending and tracking. Prepares and submits accurate weekly, monthly quarterly and annual forecasts. Completes field sales cadence requirements and ensures reports do as well
  • Reports and tracks information as requested by management
  • Drives cash flow by proper monitoring and tactics to support Open PO, Accounts Receivable and field inventory management to achieve company goals
  • Links the operations of the region’s Sales department with key Marketing internal resources to maximize overall business efficiency
  • Monitors strategies and marketplace developments and communicates regarding such matters to business partners and the internal organization
  • Provides input to Marketing and Senior Leadership on market trends, competition and field sales execution to analyze, direct and review product offerings, competition and market strategies and programs
  • Communicates key distribution and supply chain needs to business partners in order to meet customer objectives
  • Ensures that effective communication is established, maintained and enhanced with the Sales, Corporate Accounts and Marketing teams
  • Works collaboratively across functions aligned towards broader organization goals
  • Grow and maintain relationships with key surgeons and accounts
  • Provide exceptional customer service, ensuring surgeons needs are met to maintain long-term relationships. Case coverage depending on Regional needs
  • Assesses customer needs and prepares strategic plans to optimize customer satisfaction and the Company’s business goals
  • Understands customer needs and establishes specific business plans and solutions that meet those needs (short and long term) while driving business objectives
  • Supports and drives access thru strong partnering with corporate pricing and contracting team. Advocates for their area to support access for their teams
Desired Qualifications
  • Strong strategic thinking, problem-solving, and decision-making skills
  • Excellent negotiation, communication, and interpersonal skills
  • Proven ability to build relationships with high-level stakeholders and close complex deals
  • Strong business acumen to support non-revenue imperatives such as cash management and field inventory management
  • Analytical mindset with the ability to interpret sales data and market trends to make informed decisions
  • Proficiency in CRM systems and other sales management software
  • Supervisory Skills - ability to direct and manage a team of direct and indirect reports
  • Proficiency in Microsoft Office Suite (Excel, PowerPoint, Word)
  • Analytical, Entrepreneurial, Cross-functional collaboration, Process & Continuous improvement
  • Ability to manage multiple products in a fast paced environment
  • Currently, Enovis does not provide sponsorship for employment visas (e.g., H-1B) and will not offer such sponsorship in the future. Applicants must already have full-time work authorization in the United States, both now and in the future, without requiring sponsorship.

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment achieves 10% organic growth led by double-digit shoulder gains.
  • ARVIS robot deployment starts with South Africa procedure, adoption expands through 2026.
  • BTIG initiates Buy rating with $41 target on new launches in hips and knees.

What critics are saying

  • $1.18B goodwill impairment from LimaCorporate overpayment erodes R&D capital now.
  • Stryker Mako captures 60% US robotic shoulder procedures, blocks ARVIS adoption by 2027.
  • Zimmer Biomet Persona IQ steals Nebula conversions, slows recon growth by mid-2027.

What makes ENOVIS unique

  • Enovis leverages Enovis Growth Excellence system for continuous operational improvements.
  • Enovis offers ARVIS shoulder robot and Augmented Reverse Glenoid System for extremities.
  • Enovis integrates LimaCorporate acquisition to expand reconstructive implant portfolio.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at ENOVIS who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.